Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Bradford R Hirsch"'
Autor:
Bradford R Hirsch, John M Burke, Manish Agrawal, Ralph J Hauke, Thomas E Hutson, Gury Doshi, Mark T Fleming, Nicholas J Vogelzang
Publikováno v:
Journal of Kidney Cancer and VHL, Vol 3, Iss 1, Pp 23-35 (2016)
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The
Externí odkaz:
https://doaj.org/article/d0df7e06ded845189cfe1511e28aaeab
Autor:
Matthew Harker, S. Yousuf Zafar, Mark E. Fleury, Sheri Tibbs, Bradford R. Hirsch, Joseph M. Unger, Philip D'Almada, Karen Chiswell, George Tran, Kimberly D. Miller
Publikováno v:
JCO Clinical Cancer Informatics. :35-49
PURPOSE More than 20% of US clinical trials fail to accrue sufficiently. Our purpose was to provide a benchmark for better understanding clinical trial enrollment feasibility and to assess relative levels of competition for patients by cancer diagnos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c710728ab8c327cedbd5ab55c6e13a65
https://doi.org/10.1200/cci.19.00088
https://doi.org/10.1200/cci.19.00088
Autor:
Karynsa Cetin, B. Diane Reams, Rohini K. Hernandez, Anne M. Butler, Amy P. Abernethy, Alexander Liede, Robert A. Overman, Jung In Kim, Bradford R. Hirsch, M. Alan Brookhart
Publikováno v:
Pharmacoepidemiology and Drug Safety. 27:229-238
Purpose To examine the dynamics of treatment with 2 bone-targeting agents (BTAs)-denosumab and zoledronic acid-among men with bone metastases from prostate cancer. Methods Using electronic health record data from oncology practices across the US, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::424bd0d3c25429380cdcc25c6d79863d
https://doi.org/10.1002/pds.4360
https://doi.org/10.1002/pds.4360
Autor:
Daniel J. George, Patricia Creel, Greg Samsa, Azah Borham, Bradford R. Hirsch, Nrupen A. Bhavsar, Michael R. Harrison, Ronit Simantov, Amy P. Abernethy, S. Wolf
Publikováno v:
Cancer Investigation. 35:333-344
The Metastatic Renal Cell Cancer Registry, a large, nationally representative, prospective registry of patients with metastatic renal cell carcinoma (mRCC), aims to understand real-world treatment patterns and outcomes of patients with mRCC in routin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b34fdc7d022060d997819fc4caf261d
https://doi.org/10.1080/07357907.2017.1289215
https://doi.org/10.1080/07357907.2017.1289215
Autor:
Julie K. Silver, Celena Scheede-Bergdahl, Liane S. Feldman, Ann Gamsa, Sean Gilman, Andrea B. McKee, Chelsia Gillis, Nicole L. Stout, Francesco Carli, Bradford R. Hirsch
Publikováno v:
Physical Medicine and Rehabilitation Clinics of North America. 28:49-64
This review by a 10-member panel of experts in surgical prehabilitation addresses processes that may improve oncologic care. Surgical prehabilitation is the process on the continuum of care that occurs between the time of cancer diagnosis and the beg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37f5d9535020a398f05b6f7d55c7ca62
https://doi.org/10.1016/j.pmr.2016.09.002
https://doi.org/10.1016/j.pmr.2016.09.002
Autor:
Amy P. Abernethy, Bradford R. Hirsch
Publikováno v:
Personalized medicine. 9(8)
Personalized medicine is the future of clinical care. Many interpret this to mean that advances in genomic medicine will revolutionize care. However, the reality is much more complex, relying on a combination of health technology, patient engagement,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41627e4639435d3b91855d7e9c55916b
https://pubmed.ncbi.nlm.nih.gov/29776232
https://pubmed.ncbi.nlm.nih.gov/29776232
Autor:
Mark S. Walker, Amy P. Abernethy, Daniel J. George, Aaron P. Mitchell, Michael R. Harrison, Bradford R. Hirsch
Publikováno v:
Journal of Oncology Practice. 11:491-497
Although narrow eligibility criteria improve the internal validity of clinical trials, they may result in differences between study populations and real-world patients, threatening generalizability. Therefore, we evaluated whether patients treated fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8301368be6930650257cd5b484dac378
https://doi.org/10.1200/jop.2015.004929
https://doi.org/10.1200/jop.2015.004929
Autor:
Bradford R. Hirsch, Gary H. Lyman
Publikováno v:
Blood Reviews. 28:263-268
As the cost of healthcare continues to rise and patents on biologics near expiration, biosimilars are gaining visibility as a mechanism for cost reduction. Yet, the introduction of biosimilars into the U.S. market will be complex, due to the related
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6064d56246cfe482a3794136efb37eb
https://doi.org/10.1016/j.blre.2014.08.003
https://doi.org/10.1016/j.blre.2014.08.003
Autor:
Connie Chen, Beata Korytowsky, Edward J. Stepanski, Michael R. Harrison, Bradford R. Hirsch, Daniel J. George, Mark S. Walker, Amy P. Abernethy
Publikováno v:
Journal of Oncology Practice. 10:e63-e72
As new therapeutics for metastatic renal cell carcinoma (mRCC) are quickly introduced to market, comparative randomized trial evidence guiding treatment decisions is lacking, especially in the second treatment exposure and beyond. As a demonstration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17bbf925df8f22ef315691c0ad53289b
https://doi.org/10.1200/jop.2013.001180
https://doi.org/10.1200/jop.2013.001180
Autor:
S. Yousuf Zafar, Bradford R. Hirsch
Publikováno v:
Seminars in Radiation Oncology. 24:49-53
Comparative effectiveness research (CER) is critically needed in medical oncology to improve the care being delivered to oncology patients. As medical oncologists are forced to rely on insufficient data as a part of daily treatment decision making, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c65399291f4fd877a218ea5f7d2e2994
https://doi.org/10.1016/j.semradonc.2013.08.005
https://doi.org/10.1016/j.semradonc.2013.08.005